Cargando…

Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13

BACKGROUND: This study evaluated the existence of anti-drug antibodies (ADAs) before and 52 weeks after switching from intravenous infliximab (IFX) to intravenous CT-P13 in patients with rheumatoid arthritis (RA). METHODS: We performed a prospective observational study. Twenty-eight patients (7 male...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakane, Hideo, Okamura, Koichi, Inoue, Makoto, Inoue, Hiroshi, Yonemoto, Yukio, Mitomi, Hirofumi, Tsuchida, Kosei, Suto, Takahito, Kaneko, Tetsuya, Chikuda, Hirotaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727853/ https://www.ncbi.nlm.nih.gov/pubmed/36474258 http://dx.doi.org/10.1186/s41927-022-00304-9

Ejemplares similares

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

The impact of bDMARDs on postoperative complications in patients with rheumatoid arthritis: A systematic review and meta-analysis
por: Suto, Takahito, et al.
Publicado: (2023)

Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
por: Trang, D. A. M. Thuy, et al.
Publicado: (2021)

Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?
por: Tachibana, Masahiro, et al.
Publicado: (2020)

Shoulder tenderness was associated with the inflammatory changes on magnetic resonance imaging in patients with rheumatoid arthritis
por: Shinagawa, Satoshi, et al.
Publicado: (2019)

Prediction of Large Joint Destruction in Patients With Rheumatoid Arthritis Using (18)F-FDG PET/CT and Disease Activity Score
por: Suto, Takahito, et al.
Publicado: (2016)

Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT
por: Okamura, Koichi, et al.
Publicado: (2014)

The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
por: Talotta, Rossella, et al.
Publicado: (2017)

Pelvic peritonitis during biologic therapy for rheumatoid arthritis: a case report and review of the literature
por: Sasaki, Tsuyoshi, et al.
Publicado: (2014)

The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan
por: Alawneh, Khaldoon, et al.
Publicado: (2022)

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
por: Brodszky, Valentin, et al.
Publicado: (2014)

Infliximab in the treatment of rheumatoid arthritis
por: Perdriger, A
Publicado: (2009)

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
por: Baji, Petra, et al.
Publicado: (2014)

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
por: Waller, John, et al.
Publicado: (2017)

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2020)

Biologic-free remission by orthopaedic surgery in non-responder to infliximab for rheumatoid arthritis
por: Kanbe, Katsuaki, et al.
Publicado: (2015)

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2019)

A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis
por: Kameda, Hideto, et al.
Publicado: (2020)

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
por: Yoo, Dae Hyun, et al.
Publicado: (2017)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

How does infliximab work in rheumatoid arthritis?
por: Maini, Ravinder N, et al.
Publicado: (2002)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Ramsay Hunt Syndrome in a Patient with Rheumatoid Arthritis after Treatment with Infliximab
por: Nagayama, Yoshio, et al.
Publicado: (2014)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
por: Cohen, Stanley B., et al.
Publicado: (2018)

Diagnostic value of (18)F-fluorodeoxyglucose uptake parameters to differentiate rheumatoid arthritis from other types of arthritis
por: Bhattarai, Anu, et al.
Publicado: (2017)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
por: Cohen, Stanley B, et al.
Publicado: (2023)

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
por: Choe, Jung-Yoon, et al.
Publicado: (2017)

Infliximab improves vascular stiffness in patients with rheumatoid arthritis
por: Wong, M, et al.
Publicado: (2008)

Stabilization of Bilateral Progressive Rheumatoid Corneal Melt with Infliximab
por: Antao, Sheelah F., et al.
Publicado: (2012)

Dual role of interleukin-17 in pannus growth and osteoclastogenesis in rheumatoid arthritis
por: Ito, Hiroshi, et al.
Publicado: (2011)

Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results
por: Nozaki, Yuji, et al.
Publicado: (2018)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

A systematic review of infliximab in the treatment of early rheumatoid arthritis
por: Du Pan, Sophie Martin, et al.
Publicado: (2007)

The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
por: Dwivedi, Ravi C, et al.
Publicado: (2009)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sns3ecl8f13o08o8e8tnjuu95d